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Abstract
Purpose The enzymes gamma-glutamyl hydrolase (GGH) and folylpolyglutamate synthetase (FPGS) regulate intracellular 
folate concentrations needed for cell proliferation, DNA synthesis, and repair. High GGH expression affects 5-FU thymidylate 
synthase (TS) inhibition and is a risk factor for various malignancies. Here, the clinical significance of GGH and FPGS 
expression was investigated in Stage II/III gastric cancer patients undergoing postoperative adjuvant chemotherapy with S-1.
Methods Surgical specimens of cancer tissue and adjacent normal mucosa, obtained from 253 patients with previously 
untreated gastric cancer, were examined. GGH and FPGS mRNA expression was measured by qPCR to evaluate their clin-
icopathological significance in gastric cancer patients after curative resection.
Results While FPGS expression showed no significant differences between the cancerous and normal samples, GGH expres-
sion was higher in cancer tissue than in adjacent normal mucosa. High GGH expression was correlated with age, histological 
type, and vascular invasion. Overall survival (OS) of patients with high GGH mRNA expression was significantly poorer 
than of patients with low GGH expression. Multivariate analysis showed that high GGH expression was an independent 
prognostic factor of OS (HR: 2.58, 95% CI 1.29–5.16). Patients who received S-1 adjuvant treatment showed a significantly 
poor OS between high GGH/low FPGS and low GGH/high FPGS. Patients without adjuvant treatment showed no significant 
difference.
Conclusion GGH expression was significantly higher in gastric cancer tissue than in adjacent normal mucosa. High GGH 
and low FPGS expression is a useful independent predictor of poor outcomes in stage II/III gastric cancer patients undergo-
ing postoperative adjuvant chemotherapy with S-1.
Keywords Gastric cancer · Gamma-glutamyl hydrolase (GGH) · Folylpolyglutamate synthetase (FPGS) · S-1 · Prognostic 
factor
Introduction
Gastric cancer was the fifth most common in new cases 
of cancer (1,033,701 cases) and the third most common 
in cancer-related deaths (781,631 deaths) in 2018 (Bray 
et al. 2018). Curative resection and postoperative adjuvant 
chemotherapy is the standard treatment for locally advanced 
gastric cancer in Japan. Since Adjuvant Chemotherapy Trial 
of S-1 for Gastric Cancer (ACTS-GC), adjuvant chemother-
apy with S-1 is one of the standard treatments for patho-
logical TNM stage II/III gastric cancer (except pT1N2-3/
pT3N0) for the prevention of recurrence (Sakuramoto et al. 
2007; Japanese gastric cancer treatment guidelines 2014 
(ver. 4) 2017). Moreover, CLASSIC and JACCRO-07 trials 
have been used to confirm the effectiveness of capecitabine 
plus oxaliplatin (CapeOX) therapy and S-1 plus docetaxel 
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(DS) therapy; fluoropyrimidine is still the key drug used in 
the postoperative adjuvant chemotherapy for gastric cancer 
(Sakuramoto et al. 2007; Bang et al. 2012; Noh et al. 2014). 
However, the outcomes of treatment are still insufficient, 
as recurrence occurs in 20–60% of patients, even after a 
complete resection and the administration of the appropriate 
adjuvant therapy (Maehara et al. 2000; Rivera et al. 2007). 
The personalization of postoperative adjuvant chemother-
apy treatment using biomarkers is a promising strategy to 
improve the survival of patients with localized advanced 
gastric cancer. However, a specific biomarker for use in pre-
dicting the therapeutic effects of fluorinated pyrimidine and 
the long-term outcomes of patients with locally advanced 
gastric cancer has yet to be identified (Pizzorno et al. 1988; 
Shubbar et al. 2013; Melling et al. 2017).
Folic acid is a molecule which is necessary for cell prolif-
eration, DNA synthesis, and repair. Gamma-glutamyl hydro-
lase (GGH) and folylpolyglutamate synthetase (FPGS) are 
enzymes which regulate intracellular folate concentrations 
(Bailey 2010). GGH promotes the production of monogluta-
myl acid folate, a metabolite of folic acid required for DNA 
synthesis. On the other hand, FPGS catalyzes the hydrolysis 
of monoglutamate folate into polyglutamate, which has a 
high intracellular retention (Bailey 2010). Thus, GGH and 
FPGS strongly influence DNA synthesis in cancer cells.
Previous studies have reported that high GGH expression 
is a risk factor for the prognosis of various malignancies 
(Shubbar et al. 2013; Melling et al. 2017). Moreover, the 
expression of GGH and FPGS was reported to affect thymi-
dylate synthase (TS) inhibition of 5-fluorouracil (5-FU) in 
a range of malignancies (Cheradame et al. 1997; Sakamoto 
et al. 2008; Kim et al. 2013). Recently, it was reported that 
high GGH expression is a risk factor of lymph node recur-
rence after surgery in patients with stage II/III gastric can-
cer, using clinical specimens of ACTS-GC (Terashima et al. 
2017). However, the relationship between the expression of 
GGH and FPGS and the effect of S-1 in adjuvant chemother-
apy has not yet been evaluated. In this study, we examined 
the clinical significance of GGH and FPGS expression in 
patients with stage II/III gastric cancer who were undertak-
ing postoperative adjuvant chemotherapy with S-1.
Materials and methods
Patients and samples
We studied surgical specimens of cancer tissue and adja-
cent normal mucosa obtained from 253 patients with gastric 
cancer undergoing gastrectomy as the first treatment. The 
patients underwent surgery at the Department of Surgery 
(Yokohama City University), the Gastroenterological Center 
(Yokohama City Medical Center), and the Department of 
Gastrointestinal surgery (Kanagawa Cancer Center) between 
March 2002 and July 2012. Informed consent was obtained 
from each patient, with all protocols approved by the eth-
ics committees of each institute before the initiation of the 
study. All tissue samples were embedded in O.C.T. com-
pound (Sakura Finetechnical Co., Ltd., Tokyo) and immedi-
ately stored at − 80 °C until further use. None of the patients 
had any other malignancies. The specimens were stained 
with hematoxylin and eosin and examined histopathologi-
cally. Sections consisting of > 80% cancer cells were used 
to prepare total RNA.
Quantitative reverse-transcriptase polymerase 
chain reaction (qRT-PCR)
qRT-PCR was performed with iQ SYBR Green Supermix 
(Bio-Rad Laboratories). PCR was carried out in a total vol-
ume of 15 μl, which included 0.2 μg of cDNA derived from 
75 ng of RNA, 0.4 μM of each primer, 7.5 μl of iQ SYBR 
Green Supermix containing dATP, dCTP, dGTP, and dTTP 
at concentrations of 400 μM each, as well as 50 units/ml of 
iTag DNA polymerase. The PCR cycles consisted of 3 min 
at 95 °C, followed by 40 cycles of denaturation of the cDNA 
for 10 s at 95 °C, annealing for 10 s, a primer extension for 
20 s at 72 °C, followed by 10 min at 72 °C. The anneal-
ing temperature was set at 57 °C and 59 °C for GGH and 
FPGS, respectively. To distinguish specific from nonspecific 
products and primer dimmers, melting curve analyses were 
performed. To evaluate the specific mRNA expression in 
the samples, a standard curve was produced for each run, 
measuring three points of the human control cDNA (Clon-
tech Laboratories, Inc., CA, USA). The concentration of 
each sample was calculated by relating its crossing point 
to a standard curve. The measurement was performed three 
times and the average value was adopted. The PCR primer 
sequences of GGH, FPGS and β-actin, used as an internal 
control, are shown in Table 1.
Statistical analysis
Gene expression levels were compared between gastric 
cancer and adjacent normal mucosa by the Wilcoxon test. 
The expression levels of GGH and FPGS mRNA were cat-
egorized as low or high based on a cut-off value calculated 
using to the maximum Chi-square (χ2) test. The relation-
ship between mRNA expression and potential explana-
tory variables, including age, gender, tumor size, depth of 
invasion, lymph-node metastasis, distant metastasis, stage, 
lymphatic invasion, venous invasion, and histological type, 
were evaluated with the χ2 test. The associations between 
the expression of GGH and FPGS mRNA and survival 
were assessed using the Kaplan–Meier method, then com-
pared using the log-rank test. A Cox proportional-hazards 
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model was used to perform univariate analyses and step-
wise multivariate analyses to determine the risk fac-
tors. The software program SPSS (ver. 23.0; IBM Corp., 
Armonk, NY, USA) was used to perform all the statis-
tical analyses. Two‐sided P values were calculated, and 
P < 0.05 was defined as a statistically significant differ-
ence. Data were expressed as medians (range).
Results
GGH and FPGS mRNA expression in gastric cancer 
tissue and adjacent normal mucosa
The GGH mRNA expression levels were higher in can-
cer tissue (0.478 [0.000–52.951]) than in adjacent normal 
mucosa (0.000 [0.000–6.597] P < 0.001). On the other 
hand, there was no significant difference in the FPGS 
mRNA expression level between cancer tissue (3.458 
[0.000–63.019]) and adjacent normal mucosa (3.295 
[0.000–80.960] P = 0.67) (Fig. 1a, b).
Relationship of GGH and FPGS mRNA expression 
levels to clinicopathological features
The expression levels of the GGH and FPGS genes were 
categorized as low or high based on a cut-off value calcu-
lated using the maximum Chi-square test. The relationship 
of the expression level of GGH mRNA or FPGS mRNA to 
the clinicopathological features was then examined. The 
expression level of GGH mRNA was related to age, histo-
logical type, and vascular invasion. On the other hand, the 
expression level of FPGS mRNA was related to vascular 
invasion and lymphatic invasion (Table 2).
Uni- and multivariate analysis of the relationship 
of clinicopathological factors and GGH/FPGS gene 
expression levels to overall survival
Univariate Cox regression analyses found that high levels 
of GGH mRNA expression, pathological stage, and lym-
phatic invasion were the significant prognostic factors. On 
the other hand, according to multivariate Cox regression 
analysis, high levels of GGH mRNA expression, pathologi-
cal stage, lymphatic invasion, and no postoperative adjuvant 
treatment with S-1 were the independent prognostic factors. 
The expression of FPGS mRNA was not selected as a sig-
nificant prognostic factor (Table 3).
Comparison of overall survival rates by expression 
levels of GGH or FPGS mRNA in gastric cancer tissue
The median follow-up time was 1823 days. During this 
follow-up period, 127 patients died. The 5-year overall 
survival rate (OS) in patients with low and high levels of 
GGH mRNA expression were 76.8% and 61.8%, respectively 
(P = 0.017, Fig. 2a). The 5-year OS rate in patients with low 
and high levels of FPGS mRNA expression were 59.9% and 
65.0%, respectively (P = 0.425, Fig. 2b).
Stratified by whether S-1 adjuvant treatment was per-
formed or not, the OS in patients who received S-1 adjuvant 
treatment was significantly poorer in patients with high lev-
els of GGH mRNA expression than those with low levels of 
GGH mRNA expression (P = 0.043, Fig. 3a). On the other 
hand, in patients who underwent surgery alone, there was no 
significant difference in the OS between patients with high 
and low level of GGH mRNA expression (P = 0.21, Fig. 3b).
The 5-year OS in patients with various combinations 
of GGH/FPGS expression, that is, low/low, low/high, 
high/high, and high/low, was 88.9%, 73.6%, 63.5%, and 
47.8%, respectively (P = 0.019, Fig. 4). Stratified by 
Table 1  PCR primers and 
conditions Gene Primer Annealing tempera-ture (°C)
Product 
size 
(bp)
GGH
 Sense 5′-AGT TGC GTT ACA CCC TTT CTT GAC -3′ 57 151
 Antisense 5′-GCT CGC TCC AAC CGA CTG C-3′
FPGS
 Sense 5′-TTC CGC TTC CTG ACA CTC -3′ 59 116
 Antisense 5′-GGC TTC CTG ATG ATG TTG G-3′
β-Actin
 Sense 5′-AGT TGC GTT ACA CCC TTT CTT GAC -3′ 60 171
 Antisense 5′-GCT CGC TCC AAC CGA CTG C-3′
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whether postoperative adjuvant treatment with S-1 was 
performed, the OS in patients who received S-1 adju-
vant treatment was significantly poorer in patients with 
high levels of GGH mRNA expression and low levels of 
FPGS mRNA expression than those with low levels of 
GGH mRNA expression and high levels of FPGS mRNA 
expression (P = 0.039, Fig. 5a). On the other hand, there 
was no significant difference in patients who underwent 
surgery alone (P = 0.525, Fig. 5b).
Fig. 1  a Comparison of expres-
sion levels of the GGH gene 
between gastric cancer tissue 
and adjacent normal mucosa 
(P < 0.001). b Comparison of 
expression levels of the FPGS 
gene between gastric cancer tis-
sue and adjacent normal mucosa 
(P = 0.82)
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Discussion
In this study, we measured the levels of GGH and FPGS 
mRNA expression in cancer tissues and adjacent normal 
mucosa in patients with stage II/III gastric cancer. We then 
examined the relationship between the expression levels of 
these genes and the clinicopathological features and long-
term outcomes to evaluate the clinical significance of GGH 
and FPGS mRNA expression in gastric cancer tissue in 
patients with Stage II/III gastric cancer undergoing postop-
erative adjuvant chemotherapy with S-1.
First, the expression levels of GGH and FPGS mRNA 
in gastric cancer tissue and adjacent normal mucosa were 
compared. Several previous studies have compared the rela-
tive expression levels of GGH and FPGS mRNA between 
various types of cancer tissue and adjacent normal tissue 
(Kidd et al. 2005; Pollard et al. 2009; Shubbar et al. 2013). 
These studies reported that GGH mRNA expression was 
higher in cancer tissue compared to normal tissue in breast 
cancer (Shubbar et al. 2013) and bladder cancer (Pollard 
et al. 2009). Our results are consistent with these findings, 
as the expression levels of GGH mRNA were found to be 
significantly higher in the gastric cancer tissue than in the 
paired adjacent normal mucosa. As for FPGS expression, it 
has been previously reported that the expression of FPGS 
was higher in cancer tissue than normal mucosa in colorectal 
cancer (Odin et al. 2003; Kidd et al. 2005). However, in our 
study, there was no significant difference in the expression 
levels of FPGS mRNA between the cancer tissue and adja-
cent normal tissue.
Next, the relationship between the expression levels of 
GGH and FPGS mRNA and the clinicopathological features 
Table 2  Comparison of patient’s background and pathological outcomes
Variables All Patients 
(n = 253)
GGH expression P value FPGS expression P value
High group 
(n = 211)
Low group 
(n = 42)
High group 
(n = 222)
Low group 
(n = 31)
Age (years), 
median (range)
65 (38–98) 70 (48–98) 64 (38–87) < 0.001 68 (44–89) 69 (380–98) 0.46
Gender 0.94 0.25
 Male 170 (67.2%) 142 (67.3%) 28 66.7%) 152 (68.5%) 18 (58.1%)
 Female 83 (32.8%) 69 (32.7%) 14 (33.3%) 70 (31.5%) 13 41.9%)
Histological type 0.012 0.66
 Undifferentiated 140 (55.3%) 108 (51.2%) 32 76.2%) 124 (55.9%) 16 (51.6%)
 Differentiated 112 (44.3%) 102 48.3%) 10 (23.8%) 98 (44.1%) 15 (48.4%)
Tumor size (mm) 0.12 0.84
 < 65 135 (53.4%) 108 (51.2%) 27 (64.3%) 119 (53.6%) 16 (51.6%)
 65 ≤ 118 (46.6%) 103 (48.8%) 15 (35.7%) 103 (46.4%) 15 (48.4%)
Pathological T 
factor
0.80 0.32
 T1–3 119 (47.0%) 100 47.4%) 19 (45.2%) 107 (48.2%) 12 (38.7%)
 T4 134 (53.0%) 111 (52.6%) 23 (54.8%) 115 (51.8%) 19 (61.3%)
Pathological N 
factor
0.60 0.69
 N0 56 (22.1%) 48 (22.75%) 8 (19.1%) 50 (22.5%) 6 (19.4%)
 N1–3 197 (77.9%) 163 (77.3%) 34 (81.0%) 172 (77.5%) 25 (80.6%)
Stage 0.71 0.59
 II 103 (49.7%) 87 (41.2%) 16 (38.1%) 89 (40.1%) 14 (45.2%)
 III 150 (59.3%) 124 (58.8%) 26 (61.9%) 133 (59.9%) 17 (54.8%)
Vascular invasion 0.028 0.086
 v0 73 (28.9%) 55 (26.1%) 18 (42.9%) 60 (27.0%) 13 (41.9%)
 v1–3 180 (71.1%) 156 (73.9%) 24 (57.1%) 162 (73.0%) 18 (58.1%)
Lymphatic invasion 0.87 0.094
 ly0 81 (32.0%) 68 (32.2%) 13 (31.0%) 67 (30.2%) 14 (45.2%)
 ly1–3 172 (68.0%) 143 (67.8%) 29 (69.0%) 155 (69.8%) 17 (54.8%)
Adjuvant therapy 0.35 0.46
 Yes 146 (42.3%) 119 (56.4%) 27 (64.3%) 130 (58.6%) 16 (51.6%)
 No 107 (57.7%) 92 (43.6%) 15 (35.7%) 92 (41.4%) 15 (48.4%)
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in patients with stage II/III gastric cancer were examined. It 
was reported that GGH expression was significantly asso-
ciated with a high histological tumor grade (BRE grade 
III, P < 0.001), as well as ER/PR receptors in patients with 
breast cancer (Shubbar et al. 2013). As for FPGS, to the best 
of our knowledge, there are no reports. In this study, high 
levels of GGH mRNA expression were significantly cor-
related with age, histological type, and vascular invasion. 
High levels of FPGS mRNA expression, on the other hand, 
were found to be related to vascular invasion and lymphatic 
invasion.
The relationship between the expression levels of GGH 
and FPGS mRNA in cancer tissue and long-term outcomes 
in patients with stage II/III gastric cancer was then assessed. 
Several studies have previously reported that patients with 
high levels of GGH mRNA expression in cancer tissue 
resulted in significantly poor outcomes compared to patients 
with low levels of GGH mRNA expression. Melling et al. 
(2017) reported that 10-year recurrence-free survival was 
significantly higher in patients with high levels of GGH 
expression compared to patients with low level of GGH 
expression in ERG negative prostate cancer (P = 0.0002). 
Shubber et al. (2013) reported that 8-year disease-specific 
survival (DSS) was significantly different between patients 
expressing GGH (39%) and patients whose tumors were 
GGH-negative (68%, P = 0.037) in invasive breast cancer. 
In addition, univariate analysis showed that GGH expression 
exhibited a lower DSS probability, with a 2.7-fold increase 
in risk of death (P = 0.04) (Shubbar et al. 2013). As for 
FPGS, it was reported that 5-year tumor-specific survival 
(TSS) was significantly better in patients with high levels 
of FPGS mRNA expression (75%) than patients with low 
levels of FPGS mRNA expression (35%, P = 0.002). In addi-
tion, FPGS expression has been previously reported to be an 
independent significant prognostic factor of TSS in patients 
with colorectal cancer (Odin et al. 2003).
Table 3  Uni- and multivariate 
Cox proportional-hazards 
analysis of clinicopathological 
factors (overall survival)
Characteristics Number Univariate Multivariate
HR 95% CI P value HR 95% CI P value
Expression of GGH 0.02 0.006
 Low 42 1.00 1.00
 High 211 2.27 1.14–4.51 2.65 1.32–5.31
Expression of FPGS 0.43
 Low 42 1.00
 High 211 1.27 0.71–2.28
Age(years) 0.81
 < 65 135 1.00
 65 ≤ 118 1.05 0.69–1.62
Gender 0.16
 Female 83 1.00
 Male 170 1.34 0.88–2.15
Tumor size (mm) 0.84
 < 65 135 1.00
 65 ≤ 118 1.04 0.70–1.57
Histological type 0.82
 Undifferentiated 140 1.00
 Differentiated 113 1.05 070–1.58
Pathological Stage <0.001 <0.001
 II 103 1.00 1.00
 III 150 2.33 1.47–3.71 2.44 1.50–3.95
Vascular invasion 0.28
 v0 73 1.00
 v1–3 180 1.29 0.81–2.03
Lymphatic invasion 0.008 0.011
 ly0 81 1.00 1.00
 ly1–3 172 1.91 1.18–3.08 1.94 1.16–3.22
Adjuvant therapy 0.49 0.018
 Yes 146 1.00 1.00
 No 107 1.15 0.77–1.64 1.68 1.09–2.59
Journal of Cancer Research and Clinical Oncology 
1 3
Fig. 2  a Comparison of overall 
survival between high and low 
expression levels of the GGH 
gene in gastric cancer tissue 
(P = 0.017). b Comparison of 
overall survival between high 
and low expression levels of the 
FPGS gene in gastric cancer 
tissue (P = 0.425)
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Fig. 3  Comparison of overall 
survival between high and low 
expression levels of the GGH 
gene in gastric cancer tissue 
stratified by whether S-1 adju-
vant treatment was performed 
or not. a Patients who did not 
receive S-1 adjuvant treat-
ment (P = 0.21). b Patients 
received S-1 adjuvant treatment 
(P = 0.043)
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In present study, the 5-year OS was significantly poorer 
in patients with high levels of GGH mRNA expression than 
in those with low expression levels. In patients with stage II/
III gastric cancer who were administrated adjuvant chemo-
therapy with S-1, although there was no significant differ-
ence in the 5-year OS between patients with high and low 
levels of FPGS mRNA expression, the 5-year OS in patients 
with the combination of high GGH mRNA and low FPGS 
mRNA expression levels in cancer tissue was significantly 
poorer than that in the other patients.
The elucidation of the mechanism whereby high levels of 
GGH expression and low levels of FPGS expression could 
be used as prognostic biomarkers in patients with locally 
advanced gastric cancer for which the administration of 
postoperative adjuvant chemotherapy with S-1 is not cur-
rently sufficient. Previous reports have suggested the fol-
lowing mechanism: 5-FU is an active ingredient of S-1 that 
inhibits the action of thymidylate synthase (TS) and sup-
presses DNA synthesis and cell proliferation by forming a 
trimer with 5-fluorodeoxyuridylate (Fd-UMP), which is a 
metabolite of 5-FU (Longley et al. 2003; Wilson et al. 2014). 
The polyglutamate folate is produced by the folate metabo-
lism and induces the formation of the trimer (Moran 1999). 
GGH promotes the production of monoglutamyl acid folate, 
a metabolite of folic acid required for DNA synthesis. Mean-
while, FPGS catalyzes the hydrolysis of monoglutamylate 
folate into polyglutamate, which has a high intracellular 
retention (Bailey 2010). Thus, high GGH and/or low FPGS 
activity reduces 5,10-methylenetetrahydrofolic acid, as well 
as the TS, which can bind to 5,10-methylenetetrahydrofolic 
acid. As a result, it is possible that a small amount of 5-FU 
can exert a TS inhibitory effect in patients with high GGH 
and/or low FPGS activity (Moran 1999). These mechanisms 
indicated that the outcomes of patients with high levels of 
GGH expression and low levels of FPGS expression in can-
cer tissue were poorer than the other patients. Moreover, 
when combined with our results, these findings suggest 
that a combination of high GGH expression and low FPGS 
expression in cancer tissue could be used as prognostic bio-
markers in patients with locally advanced gastric cancer 
undergoing postoperative adjuvant chemotherapy with S-1 
after curative resection.
This study has several limitations. First, the study exam-
ined only mRNA expression in gastric cancer tissues. Con-
sidering its clinical utility as a biomarker, future studies 
should examine both mRNA and protein expression levels 
in the same specimen. Second, there was an issue regarding 
the heterogeneity of the gastric cancer tissue. The sample 
from which the mRNA was extracted was a 5-mm square 
stomach cancer tissue, including the deepest part, which, 
however, did not completely represent the entire tumor. 
Third, since GGH and FPGS have contrasting effects, the 
Fig. 4  Comparison of overall 
survival between high and low 
expression levels of the GGH/
FPGS gene in gastric cancer 
tissue (P = 0.019)
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Fig. 5  Comparison of overall 
survival between high and low 
expression levels of the GGH/
FPGS gene in gastric cancer 
tissue stratified by whether S-1 
adjuvant treatment was per-
formed or not. a Patients who 
did not receive S-1 adjuvant 
treatment (P = 0.525). b Patients 
received S-1 adjuvant treatment 
(P = 0.039)
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prognosis of the high GGH/low FPGS group could be pre-
dicted to be the worst, and, inversely, that of the low GGH/
high FPGS group the best. The present study demonstrated 
that a significant difference was observed when comparing 
the OS in the four groups based on different combinations of 
GGH and FPGS mRNA expression. In addition, there was 
an identically significant difference in the OS of the four 
groups with patients that had received S-1 adjuvant treat-
ment and the analysis of the two groups with high or low 
GGH. Although the obtained result was different from the 
hypothesis, which stated that the prognosis of the low GGH/
high FPGS group would be the best, the number of low 
GGH/low FPGS patients was nine, which may be the cause 
of the lack of statistical power. As such, it is possible that the 
combination of GGH/FPGS mRNA may have an enhanced 
accuracy as a biomarker.
In conclusion, high levels of GGH mRNA expression and 
low levels of FPGS mRNA expression in cancer tissue may 
be useful predictive biomarkers for the survival of patients 
with stage II/III gastric cancer undergoing postoperative 
adjuvant chemotherapy with S-1 after radical resection. It 
would be interesting for future studies to verify the possibil-
ity of personalizing treatments by selecting the appropriate 
regimen based on the expression levels of GGH and FPGS 
for patients with locally advanced gastric cancer in a clini-
cal trial.
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